Peptide Receptor Radionuclide Therapy in Patients with Somatostatin Receptor-Positive Neuroendocrine Tumors

Martijn van Essen, Dik J. Kwekkeboom, Wouter W. de Herder, Lisa Bodei, Boen L R Kam, Marion de Jong, Roelf Valkema, Eric P. Krenning

Research output: Chapter in Book/Report/Conference proceedingChapter

Original languageEnglish
Title of host publicationMonoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer
PublisherJohn Wiley and Sons
Pages121-138
Number of pages18
ISBN (Print)9780470243725
DOIs
Publication statusPublished - Jul 15 2010

Keywords

  • Improving PRRT and future directions
  • Peptide Receptor Radionuclide Therapy (PRRT) in patients - with somatostatin receptor-positive neuroendocrine tumors
  • PRRT with radiolabeled somatostatin analogues - treatment modality for patients with inoperable or metastasized endocrine GEP tumors

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

van Essen, M., Kwekkeboom, D. J., de Herder, W. W., Bodei, L., Kam, B. L. R., de Jong, M., Valkema, R., & Krenning, E. P. (2010). Peptide Receptor Radionuclide Therapy in Patients with Somatostatin Receptor-Positive Neuroendocrine Tumors. In Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer (pp. 121-138). John Wiley and Sons. https://doi.org/10.1002/9780470613214.ch4